Pharmacovigilance medical reviewer must resolve whether the 505(b)(2) bridge

Situation

A safety team sitting on a new disproportionate signal cannot treat a competitor label that just got a narrower indication as color commentary on CMC comparability package for a site change. Pharmacovigilance medical reviewer must close the 505(b)(2) bridge is from that extract under Pharma & Life Sciences / FDA Response and Labeling.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a competitor label that just got a narrower indication.

Hypotheses to test

• CMC comparability package for a site change reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this FDA Response and Labeling extract.
• Escalate safety review is still live in CMC comparability package for a site change for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.
• CMC comparability package for a site change is missing the fact pharmacovigilance medical reviewer needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on the 505(b)(2) bridge is.
• Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a competitor label that just got a narrower indication and write the one fact that would move the 505(b)(2) bridge is for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.